The stock of Precision Biosciences Inc (DTIL) has gone down by -11.84% for the week, with a -5.68% drop in the past month and a -15.13% drop in the past quarter. The volatility ratio for the week is 3.68%, and the volatility levels for the past 30 days are 3.76% for DTIL. The simple moving average for the past 20 days is -12.84% for DTIL’s stock, with a -29.87% simple moving average for the past 200 days.
Is It Worth Investing in Precision Biosciences Inc (NASDAQ: DTIL) Right Now?
Company’s 36-month beta value is 1.46.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DTIL is 2.97M, and currently, short sellers hold a 19.23% ratio of that floaft. The average trading volume of DTIL on June 25, 2025 was 129.60K shares.
DTIL) stock’s latest price update
Precision Biosciences Inc (NASDAQ: DTIL) has experienced a rise in its stock price by 7459954 compared to its previous closing price of 4.57. However, the company has seen a fall of -11.84% in its stock price over the last five trading days. businesswire.com reported 2025-06-25 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). “The receipt of Rare Pediatric Disease Designation highlights the significant.
Analysts’ Opinion of DTIL
Many brokerage firms have already submitted their reports for DTIL stocks, with BMO Capital Markets repeating the rating for DTIL by listing it as a “Outperform.” The predicted price for DTIL in the upcoming period, according to BMO Capital Markets is $34 based on the research report published on January 10, 2025 of the current year 2025.
Guggenheim, on the other hand, stated in their research note that they expect to see DTIL reach a price target of $19. The rating they have provided for DTIL stocks is “Buy” according to the report published on April 30th, 2024.
BMO Capital Markets gave a rating of “Outperform” to DTIL, setting the target price at $7 in the report published on June 17th of the previous year.
DTIL Trading at -14.50% from the 50-Day Moving Average
After a stumble in the market that brought DTIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.05% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DTIL starting from Buehler Kevin, who purchase 4,523 shares at the price of $4.67 back on Mar 26 ’25. After this action, Buehler Kevin now owns 13,235 shares of Precision Biosciences Inc, valued at $21,122 using the latest closing price.
Brown Melinda, the Director of Precision Biosciences Inc, purchase 1,839 shares at $4.75 during a trade that took place back on Mar 26 ’25, which means that Brown Melinda is holding 9,057 shares at $8,735 based on the most recent closing price.
Stock Fundamentals for DTIL
Current profitability levels for the company are sitting at:
- -0.86 for the present operating margin
- 1.0 for the gross margin
The net margin for Precision Biosciences Inc stands at -0.43. The total capital return value is set at -0.39. Equity return is now at value -50.81, with -14.22 for asset returns.
Based on Precision Biosciences Inc (DTIL), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -42.87. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -28.22.
Currently, EBITDA for the company is 13.53 million with net debt to EBITDA at 4.58. When we switch over and look at the enterprise to sales, we see a ratio of -0.55. The receivables turnover for the company is 12785.25for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.62.
Conclusion
In a nutshell, Precision Biosciences Inc (DTIL) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
